BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

505 related articles for article (PubMed ID: 18550490)

  • 1. [Advances on mutant p53 research].
    Li DH; Zhang LQ; He FC
    Yi Chuan; 2008 Jun; 30(6):697-703. PubMed ID: 18550490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant p53: an oncogenic transcription factor.
    Strano S; Dell'Orso S; Di Agostino S; Fontemaggi G; Sacchi A; Blandino G
    Oncogene; 2007 Apr; 26(15):2212-9. PubMed ID: 17401430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein.
    Frebourg T; Kassel J; Lam KT; Gryka MA; Barbier N; Andersen TI; Børresen AL; Friend SH
    Proc Natl Acad Sci U S A; 1992 Jul; 89(14):6413-7. PubMed ID: 1631137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.
    Sigal A; Rotter V
    Cancer Res; 2000 Dec; 60(24):6788-93. PubMed ID: 11156366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
    Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
    J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.
    Yue X; Zhao Y; Xu Y; Zheng M; Feng Z; Hu W
    J Mol Biol; 2017 Jun; 429(11):1595-1606. PubMed ID: 28390900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53.
    Pfister NT; Prives C
    Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 27836911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in p53 research: an interdisciplinary perspective.
    Olivier M; Petitjean A; Marcel V; Pétré A; Mounawar M; Plymoth A; de Fromentel CC; Hainaut P
    Cancer Gene Ther; 2009 Jan; 16(1):1-12. PubMed ID: 18802452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant p53 proteins: between loss and gain of function.
    Strano S; Dell'Orso S; Mongiovi AM; Monti O; Lapi E; Di Agostino S; Fontemaggi G; Blandino G
    Head Neck; 2007 May; 29(5):488-96. PubMed ID: 17123310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Crippling p53 activities via knock-in mutations in mouse models.
    Iwakuma T; Lozano G
    Oncogene; 2007 Apr; 26(15):2177-84. PubMed ID: 17401426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant p53 in colon cancer.
    Nakayama M; Oshima M
    J Mol Cell Biol; 2019 Apr; 11(4):267-276. PubMed ID: 30496442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF).
    Tan BS; Tiong KH; Choo HL; Chung FF; Hii LW; Tan SH; Yap IK; Pani S; Khor NT; Wong SF; Rosli R; Cheong SK; Leong CO
    Cell Death Dis; 2015 Jul; 6(7):e1826. PubMed ID: 26181206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Mutant p53 Proteins on Glycolysis and Mitochondrial Metabolism.
    Eriksson M; Ambroise G; Ouchida AT; Lima Queiroz A; Smith D; Gimenez-Cassina A; Iwanicki MP; Muller PA; Norberg E; Vakifahmetoglu-Norberg H
    Mol Cell Biol; 2017 Dec; 37(24):. PubMed ID: 28993478
    [No Abstract]   [Full Text] [Related]  

  • 15. Mutant p53 partners in crime.
    Kim MP; Lozano G
    Cell Death Differ; 2018 Jan; 25(1):161-168. PubMed ID: 29099488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Li-Fraumeni syndrome: a p53 family affair.
    Iwakuma T; Lozano G; Flores ER
    Cell Cycle; 2005 Jul; 4(7):865-7. PubMed ID: 15917654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain of function of p53 cancer mutants in disrupting critical DNA damage response pathways.
    Song H; Xu Y
    Cell Cycle; 2007 Jul; 6(13):1570-3. PubMed ID: 17598983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 mutations in cancer.
    Muller PA; Vousden KH
    Nat Cell Biol; 2013 Jan; 15(1):2-8. PubMed ID: 23263379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disarming mutant p53 oncogenic function.
    Girardini JE; Marotta C; Del Sal G
    Pharmacol Res; 2014 Jan; 79():75-87. PubMed ID: 24246451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.